SCHEMBL4298013

SCHEMBL4298013

Cc1ncc(C(=O)O)c(C2CCCO2)n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.38
MEN1 O00255 1/20 0.38
APEX1 P27695 1/20 0.38
KMT2A Q03164 1/20 0.38
PRKAB2 O43741 5/20 0.35
PRKAG1 P54619 5/20 0.35
PRKAA2 P54646 5/20 0.35
PRKAA1 Q13131 5/20 0.35
PRKAG3 Q9UGI9 5/20 0.35
PRKAG2 Q9UGJ0 5/20 0.35
PRKAB1 Q9Y478 5/20 0.35
HPGD P15428 1/20 0.34
HCAR3 P49019 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
MAPK1 P28482 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014810 0.85 CFTR (0.44) HSD11B1KMT2AHPGDSMN1; SMN2
SCHEMBL1013178 0.83 MEN1 (0.40) HSD11B1MEN1APEX1KMT2A
SCHEMBL1013177 0.83 MEN1 (0.40) HSD11B1MEN1APEX1KMT2A
SCHEMBL1014376 0.83 MEN1 (0.40) HSD11B1MEN1APEX1KMT2A
SCHEMBL1015020 0.78 HSD11B1 (0.52) HSD11B1KMT2AHPGDSMN1; SMN2
SCHEMBL1015670 0.77 HSD11B1 (0.50) HSD11B1KMT2AHPGDSMN1; SMN2TMEM97
SCHEMBL1015366 0.77 HSD11B1 (0.62) HSD11B1MEN1KMT2ASMN1; SMN2
SCHEMBL1015365 0.77 HSD11B1 (0.62) HSD11B1MEN1KMT2ASMN1; SMN2
SCHEMBL1015671 0.77 HSD11B1 (0.62) HSD11B1MEN1KMT2ASMN1; SMN2
SCHEMBL28059199 0.77 HSD11B1 (0.51) HSD11B1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 HSD11B1 2/4885MEN1 1994/4885APEX1 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.